Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)

Autor: Campbell, C. M., Lorusso, S., Dispenzieri, A., Kristen, A. V., Maurer, M. S., Rapezzi, C., Lairez, O., Drachman, B., Garcia-Pavia, P., Grogan, M., Chapman, D., Amass, L., Emdin, M., Hanna, M., Azevedo, O., Cirami, C. L., Jacoby, D., Costello, J. G., Slosky, D., Moelgaard, H., Hummel, S., Nativi-Nicolau, J., Murali, S., Fine, N., Jeon, E. -S., Shah, S., Witteles, R., Lenihan, D., Waddington-Cruz, M., Sekijima, Y., Tallaj, J., Mueller, C., Van Cleemput, J., Plante-Bordeneuve, V., Nienhuis, H., Quan, D., Steidley, D., Schmidt, H., Wixner, J., Polydefkis, M., Ralph, J., Ventura, H., Zivkovic, S., Gess, B., Torron, R. F., Gottlieb, S., Cotts, W., Tauras, J., Sarswat, N., Moreno, J. G., Parman, Y., Luo, J.

Publikováno v: Cardiology and therapy. 11(3)

Wild-type transthyretin amyloidosis (ATTRwt amyloidosis) is a progressive disease resulting from the accumulation of wild-type transthyretin (TTR) amyloid fibrils, and is diagnosed primarily in males. This analysis examined sex differences in patient

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b7107046c1781c9e3bc49dc171bfd4e
https://pubmed.ncbi.nlm.nih.gov/35583798

Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin Amyloidosis: Insights From THAOS

Autor: Caponetti, A. G., Rapezzi, C., Gagliardi, C., Milandri, A., Dispenzieri, A., Kristen, A. V., Wixner, J., Maurer, M. S., Garcia-Pavia, P., Tournev, I., Plante-Bordeneuve, V., Chapman, D., Amass, L., van Cleemput, J., Waddington-Cruz, M., Schmidt, H., Dillmann, K. -U., Molgaard, H., Moreno, J. G., Costello, J. G., Beamud, F. M., Davila, L. G., Adams, D., Inamo, J., Lairez, O., Vita, G., Merlini, G., Cirami, C. L., Luigetti, M., Emdin, M., Sekijima, Y., Jeon, E. -S., Oh, J., Gonzalez Duarte Briseno, M. A., Nienhuis, H., Coelho, T., Conceicao, I., Azevedo, O., Badelita, S., Press, R., Parman, Y., Shah, S., Quan, D., Marburger, T., Polydefkis, M., Witteles, R., Gottlieb, S., Sarswat, N., Drachman, B., Steidley, D., Hummel, S., Slosky, D., Jacoby, D., Nativi-Nicolau, J., Tauras, J., Zivkovic, S., Tallaj, J., Lenihan, D.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3709::da1446f1e60664906d1418d8099eaa5e
https://hdl.handle.net/11392/2472809

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network.

Autor: Ling W (AUTHOR), Amass L (AUTHOR), Shoptaw S (AUTHOR), Annon JJ (AUTHOR), Hillhouse M (AUTHOR), Babcock D (AUTHOR), Brigham G (AUTHOR), Harrer J (AUTHOR), Reid M (AUTHOR), Muir J (AUTHOR), Buchan B (AUTHOR), Orr D (AUTHOR), Woody G (AUTHOR), Krejci J (AUTHOR), Ziedonis D (AUTHOR), Buprenorphine Study Protocol Group (CORPORATE AUTHOR)

Publikováno v: Addiction. Aug2005, Vol. 100 Issue 8, p1090-1100. 11p.